Bausch + Lomb (NYSE:BLCO – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $21.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 22.74% from the company’s previous close.
A number of other equities analysts also recently issued reports on BLCO. Citigroup increased their price target on Bausch + Lomb from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Evercore set a $17.00 price objective on Bausch + Lomb in a research report on Monday, July 6th. Weiss Ratings raised Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 21st. UBS Group initiated coverage on Bausch + Lomb in a research report on Thursday, July 30th. They set a “buy” rating and a $21.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft set a $16.00 price target on shares of Bausch + Lomb in a research note on Thursday, April 30th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bausch + Lomb presently has a consensus rating of “Hold” and a consensus price target of $18.75.
Get Our Latest Stock Analysis on Bausch + Lomb
Bausch + Lomb Stock Down 0.8%
Bausch + Lomb (NYSE:BLCO – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.01). Bausch + Lomb had a positive return on equity of 4.14% and a negative net margin of 3.21%.The firm had revenue of $1.39 billion during the quarter, compared to analyst estimates of $1.37 billion. During the same quarter last year, the company posted ($0.18) EPS. The company’s revenue was up 9.1% on a year-over-year basis. On average, research analysts forecast that Bausch + Lomb will post 0.81 EPS for the current year.
Insiders Place Their Bets
In other Bausch + Lomb news, Director Eschenbach Andrew C. Von sold 12,500 shares of Bausch + Lomb stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $16.50, for a total transaction of $206,250.00. Following the sale, the director owned 69,792 shares of the company’s stock, valued at $1,151,568. The trade was a 15.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Frederick Munsch sold 52,900 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $16.78, for a total transaction of $887,662.00. Following the completion of the sale, the chief accounting officer owned 45,831 shares of the company’s stock, valued at $769,044.18. This trade represents a 53.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 71,459 shares of company stock worth $1,194,370 in the last 90 days. 1.45% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Bausch + Lomb
A number of large investors have recently made changes to their positions in BLCO. Cetera Investment Advisers lifted its position in Bausch + Lomb by 3.9% during the fourth quarter. Cetera Investment Advisers now owns 18,713 shares of the company’s stock worth $320,000 after buying an additional 711 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in Bausch + Lomb by 38.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,757 shares of the company’s stock valued at $64,000 after buying an additional 1,039 shares in the last quarter. Handelsbanken Fonder AB increased its stake in shares of Bausch + Lomb by 5.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company’s stock worth $364,000 after acquiring an additional 1,100 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Bausch + Lomb by 104.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after acquiring an additional 1,136 shares during the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of Bausch + Lomb by 31.2% during the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after acquiring an additional 1,403 shares during the period. 11.07% of the stock is currently owned by hedge funds and other institutional investors.
Bausch + Lomb Company Profile
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Read More
- Five stocks we like better than Bausch + Lomb
- CrowdStrike’s “Mythos Moment” Tests the Bigger AI Security Trade
- 3 Stocks Facing New Pressure From Section 338 Tariffs on Canadian Goods
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.
